Project Grant R01HL174773
Award Date
8/1/24
Completion Date
4/30/29
Dollars Obligated
$270K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,845,871 to the University of Kansas Medical Center Research Institute (KUMCRI) to develop novel gene editing therapies for cystic fibrosis (CF). The key objectives are to:
Use a CRISPR-based "homology-independent targeted integration" (HITI) approach to permanently correct the CFTR gene defect in airway epithelial cells, including...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) of the Department of Health and Human Services is focused on developing chemically inducible split base editors for precise and controllable in vivo genome editing. The $667,704 award, with a project period from February 1, 2025 to November 30, 2028, supports research conducted by the Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to evaluate the safety and efficacy of using an adeno-associated virus type 1 (AAV1) vector containing a truncated cystic fibrosis transmembrane conductance regulator (CFTR) for gene therapy to treat cystic fibrosis. The $818,734 award will be used to assess the toxicology, pharmacology, and therapeutic effects of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
This federal Project Grant award of $629,319 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research will support research by Emory University to investigate mechanisms for overcoming refractory defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The research aims to determine how depletion of specific ribosomal proteins can rescue the synthesis and assembly of CFTR nonsense variants, with the goal of...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research focused on developing a novel treatment for familial hypercholesterolemia (FH). The project aims to deliver CRISPR-Cas9 gene editing components into hepatocytes (liver cells) using non-viral delivery methods, then transplant the engineered cells to replace diseased cells and lower cholesterol and triglyceride levels. Key activities include:
Comparing...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $320,251 to Ogb5, Inc. to develop a non-viral nanoparticle gene therapy delivery platform to treat cystic fibrosis and other chronic lung diseases. The project aims to demonstrate that the company's proprietary DNA and RNA nanoparticle technology can successfully deliver therapeutic levels of the cystic fibrosis transmembrane...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $756,875 to the University of Cincinnati to conduct research on the role of neutrophil extracellular traps (NETs) in mucoobstructive lung diseases like cystic fibrosis. The key objectives are to:
Investigate how NET-mediated cleavage of the epithelial junction protein E-cadherin activates inflammatory signaling pathways in bronchial...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is providing $750,672 to Stanford University to conduct research on cellular protein quality control (PQC) machinery that affects the trafficking and degradation of the CFTR protein, a key factor in cystic fibrosis (CF).
The study aims to use CRISPR-based pharmacogenomic analysis to identify PQC genes that govern the stability of the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on studying the impact of highly effective modulator therapy (HEMT) on the pulmonary and pancreatic function of young children with cystic fibrosis (CF).
The $2,862,085.00 grant, awarded on May 15, 2024, will support a 5-year study of 30 CF children aged 2-5 years old. The research aims to: 1) Determine the effect of HEMT on...